Renal Alteration
Conditions
Keywords
Renal function consecutive to pre-eclampsia
Brief summary
The purpose of the Post-preeclampsia Renal Project is to investigate the renal function of preeclamptic women after delivery, and to determine whether the anti-hypertensive drug named benazepril efficiently improves the dysfunctions observed.
Detailed description
Several epidemiological studies suggest that the risk of death from cardiovascular causes among women with preeclampsia may be increased, and that preeclampsia contrary to what has been long thought, is not cured with delivery. Preeclampsia has long been considered a 2-stage disease, stage one corresponding to an impaired placental perfusion resulting from abnormal spiral artery remodeling, and stage two corresponding to the maternal manifestations of disease, characterized by hypertension and proteinuria. However, preeclampsia might include an additional, 3rd stage, that of the post-partum period (Gammill & Roberts, 2007) This phase deserves to be investigated. In particular, it is crucial to determine whether the changes that occur in renal hemodynamics during preeclampsia are reversible after more than 6 weeks, and whether PEC women are salt-sensitive after delivery. The link between chronic kidney disease and cardiovascular mortality is well established. An independent, graded association exists between a reduced GFR and the risk of death, cardiovascular events, and hospitalization (Go et al, 2004). Besides, salt-sensitivity is associated with an increased cardiovascular and renal risk (Franco & Oparil, 2006). The Renal Post PEC study aims at establishing if the renal dysfunctions that occur in PEC women can be reversed by the administration of inhibitors of the renin-angiotensin system that are known to improve cardiovascular and renal risk profiles in hypertensive patients. By virtue of their potent renal vasodilatory properties and favourable remodelling of the GBM, ACE inhibitors may improve salt-sensitivity, endothelial function, renal plasma flow and GFR, and general renal prognosis in women who experienced from preeclampsia.
Interventions
DRUGPlacebo
Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
Sponsors
University Hospital, Geneva
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Pre-selection Criteria: * Normotensive women with no proteinuria before the 20th week of gestation AND * Women with hypertension (BP ≥140/90 mm Hg) and proteinuria (≥ 0.3 g /24h or 2++ dipstick) after the 20th week of gestation Inclusion Criteria: * Clearance of creatinine ≤ 80 ml/min (Gault et Cockcroft) * Serum creatinine ≥ 80 µmol/L * Microalbuminuria comprised between 30 and 300 mg/d and/or a urinary spot with microalbuminuria/creatinine ratio ≥ 3.5 and/or macroalbuminuria (24h urinary albumin excretion ≥ 0.500 mg) * BP ≥ 140/90 mm Hg OR ongoing antihypertensive treatment * CRP ≥ 4 mg/dL
Exclusion criteria
* Those unlikely to co-operate in the study * Those who refuse to use appropriate contraceptive measures during the treatment period (intrauterine device, oral contraceptives, condom, diaphragm) * Those with a history of pre-term delivery * Those with known history of severe allergic reaction * Those who consume drugs * Aged \< 18 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| microalbuminuria excretion rate (spot or 24h) | Baseline; 1 week + 24 weeks after treatment start |
| eGFR | Baseline; 1 week + 24 weeks after treatment start |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Filtration fraction % | Baseline; 1 week + 24 weeks after treatment start | — |
| 24h Ambulatory Blood Pressure | Baseline; 1 week and 24 weeks after treatment start | Mean; diurnal; nocturnal |
| Effective Renal Plasma Flow | Baseline; 1 week and 48 weeks after treatment start | — |
| Adverse Events | From signature of informed consent until last follow-up visit (36 months after treatment start) | — |
Countries
Switzerland
Outcome results
None listed